Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26016465 | 1.00 | HRH3 (0.35) | HRH3CYP2C19 | |
| SCHEMBL13500455 | 1.00 | HRH3 (0.35) | HRH3CYP2C19 | |
| SCHEMBL15223075 | 1.00 | HRH3 (0.35) | HRH3CYP2C19 | |
| SCHEMBL19420783 | 1.00 | HRH3 (0.35) | HRH3CYP2C19 | |
| SCHEMBL19420770 | 1.00 | HRH3 (0.35) | HRH3CYP2C19 | |
| SCHEMBL26016462 | 1.00 | HRH3 (0.35) | HRH3CYP2C19 | |
| SCHEMBL4505808 | 0.94 | HRH3 (0.33) | HRH3CYP2C19 | |
| SCHEMBL19420768 | 0.93 | HRH3 (0.40) | HRH3 | |
| SCHEMBL19420782 | 0.93 | HRH3 (0.40) | HRH3 | |
| SCHEMBL23921531 | 0.91 | HRH3 (0.39) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067952-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-11858917-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| US-11725064-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | NOVARTIS AG (CH) | 2023-06-06 | — | — | US | disclosed |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | NOVARTIS AG (CH) | 2023-06-06 | — | — | US | disclosed |
| US-20150110742-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMS) | YALE UNIVERSITY (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150087609-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | YALE UNIVERSITY | 2015-03-26 | — | — | US | disclosed |
| US-20140308342-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-16 | — | — | US | disclosed |
| US-8859509-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2014-10-14 | — | — | US | disclosed |
| US-8852630-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130245040-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-19 | — | — | US | disclosed |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | BYONDIS B.V. (NL) | 2013-08-29 | — | — | US | disclosed |
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120034295-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY | 2012-02-09 | — | — | US | disclosed |
| US-20110201563-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140308342-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | PLAUR, CD47, CD14 | HRH3 1958/4885CYP2C19 4826/4885 |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | MIF, ASGR1, FCGR2A | HRH3 2606/4885CYP2C19 2671/4885 |
| US-11725064-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | BRDT, PAICS, KLK3 | HRH3 1307/4885CYP2C19 4736/4885 |
| US-20120034295-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | HRH3 1307/4885CYP2C19 4736/4885 |
| US-20150087609-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | CD4, HAVCR2, CD74 | HRH3 683/4885CYP2C19 2874/4885 |
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | VIP, SGTA, NGLY1 | HRH3 4463/4885CYP2C19 4507/4885 |
| US-20150110742-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMS) | TLR3, TLR4, TLR1 | HRH3 359/4885CYP2C19 3964/4885 |
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | FUT5, FUT6, SIGLEC7 | HRH3 3740/4885CYP2C19 4441/4885 |
| US-20240067952-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | PLAUR, CD47, CD14 | HRH3 1958/4885CYP2C19 4826/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | HRH3 3523/4885CYP2C19 4865/4885 |
| US-11858917-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | CD4, HAVCR2, CD2 | HRH3 207/4885CYP2C19 4511/4885 |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | ZC3HAV1, TYMP, ZC3HAV1L | HRH3 2034/4885CYP2C19 91/4885 |
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2BP2 | HRH3 265/4885CYP2C19 4660/4885 |
| US-20110201563-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | HRH3 1307/4885CYP2C19 4736/4885 |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | HRH3 1307/4885CYP2C19 4736/4885 |
| US-20130245040-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2 | HRH3 207/4885CYP2C19 4511/4885 |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | PCNA, DCLRE1A, CDC5L | HRH3 1777/4885CYP2C19 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.